Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76Urinary Bladder Neoplasms 20Neoplasms 11Carcinoma, Transitional Cell 8Non-Muscle Invasive Bladder Neoplasms 6Lung Neoplasms 6Carcinoma, Renal Cell 6Neoplasm Metastasis 5Breast Neoplasms 4Testicular Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma in Situ 3Adenocarcinoma 3Acute Kidney Injury 3Uterine Cervical Neoplasms 2Prostate CA 2Melanoma 2Liver Neoplasms 2Kidney Failure, Chronic 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Critical Illness 2Colonic Neoplasms 2Agnosia 2

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Renal Pelvis and Ureter Urothelial Carcinoma × Genitourinary × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡